Back

Argobio Portfolio Company Temper Bio Wins i-Lab Innovation Award for Groundbreaking Work in Chronic Inflammatory Disease Treatments


20/09/2024



  • Temper Bio is revolutionizing the treatment of chronic inflammatory diseases with a novel approach based on the neurokine TAFA4. The company is extending this breakthrough therapy to address neuro-inflammation, an emerging therapeutic field with high unmet medical needs.
 

 

Paris, France, September 20th, 2024 – Temper Bio, a biotechnology company co-founded by Argobio, has been awarded the prestigious i-Lab Innovation Award. Temper Bio develops new analogs of TAFA4, a neurokine proved to be an efficient inflammation modulating agent.
 
This project is based on the research work of Sophie Ugolini, CIML (Centre d'Immunologie de Marseille-Luminy), who has also been awarded the 2023 Impulscience prize (€2.5 million in funding).
 
This recognition further validates the company's cutting-edge work in expanding TAFA4's therapeutic potential into neuro-inflammation. Neuro-inflammation is gaining recognition as a critical driver of neurodegenerative diseases, yet there are few therapeutic options currently available. Temper Bio's research aims to address this gap by leveraging TAFA4’s unique properties to modulate immune responses within the central nervous system.
 
The grant from i-Lab, one of France’s most prestigious innovation competitions, will enable Temper Bio to advance develop new analogs able to cross the blood-brain barrier and test these analogs into preclinical models of Multiple Sclerosis.
 
Rémi Soula, Partner and Entrepreneur in Residence, said: “We are very grateful to bpifrance and ADEME for this i-Lab Award that will accelerate the development of our innovative products, especially in the hot field of neuroinflammation. New therapeutic approaches are highly needed for treatment of inflammation. This award is a recognition of the uniqueness of our therapeutic approach, but also of the outstanding work performed by the team, both at Argobio and at Sophie Ugolini’s laboratory. This is the opportunity to thank all the persons involved for their support and commitment.”
 
Argobio Studio, a pan-European biotech Start-up Studio, has been supporting Temper Bio since its inception, providing operational expertise, strategic guidance, and financial backing. Argobio’s team of experienced entrepreneurs and scientific leaders have helped shape the company’s vision and foster its growth in an intensely competitive market.
 
 
About Argobio Studio
Argobio, a start-up studio based in Paris, France, specializes in transforming cutting-edge innovations into groundbreaking biotech companies. The studio sources early-stage therapeutic projects from leading European academic research institutions, focusing on rare diseases, neurological disorders, oncology, and immunology. By selecting and incubating these projects, Argobio aims to develop them into fully-fledged biotech companies, advancing them to significant Series A financing. With a team of highly experienced biotech entrepreneurs, the studio offers extensive expertise in novel drug discovery and development.



Rémi Soula
Partner & EIR


Rémi Soula, Founding Partner and Entrepreneur in Residence at Argobio, co-founded Adocia (Euronext Paris: ADOC), a French public biotech company, where he was head of Business Development and Legal Affairs. Over his 14 years at Adocia, he has been in charge for several large licensing deals and partnerships with pharmaceutical companies in the US and China, and he has actively participated to the financing rounds and the IPO of the company. Prior to Adocia, he was Senior Manager at Avadel Pharmaceuticals (NASDAQ: AVDL, formerly Flamel Technologies SA). He has also been on the board of several companies, including Cellnovo. (Euronext: CLNV), a former French public medtech company. He is co-inventor on more than thirty patent families. Rémi holds a PhD in Chemistry from University Claude Bernard Lyon 1 and an executive MBA from HEC Paris.